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Background/aim: The aim of this study was to describe the results of amniotic membrane transplantation (AMT) in patients with
bacterial and herpetic stromal keratitis.
Materials and methods: This was a retrospective chart review study including 42 patients with herpetic keratitis (group 1) and 42
patients with bacterial keratitis (group 2). AMT was performed in addition to antimicrobial therapy. Topical steroids were administered
after surgery. The outcome parameters evaluated were epithelialization time, decrease of stromal inflammation, and uncorrected visual
acuity (UCVA).
Results: The average age of our patients was 55.85 ± 19.07 years, and average follow-up was 14.70 ± 11.75 months. The period of
epithelialization was 19.23 ± 7.32 days in the herpetic group and 19.31 ± 6.30 days in the bacterial group. Descemetocele developed in
2 patients of the herpetic group. Other patients in both groups completed epithelialization after AMT procedures with varying amounts
of corneal scarring. The bacterial group showed an improvement in UCVA, but the herpetic group showed no improvement in UCVA.
Conclusion: AMT is a convenient approach for the treatment of corneal keratitis resistant to conventional treatment and allows the use
of early topical steroid application. It provides patients with corneal scarring an opportunity for subsequent keratoplasty by arresting
the inflammatory response.
Key words: Amniotic membrane transplantation, bacterial keratitis, herpetic keratitis, topical steroids

1. Introduction
Microbial keratitis or infectious corneal ulcer is due
to the proliferation of microorganisms and associated
inflammation, and tissue destruction within the corneal
tissue. It is a potentially sight-threatening condition (1).
Various mechanisms are involved in the pathogenesis of this
corneal destruction; they include production of bacterial
enzymes and toxins that injure cellular components and
the extracellular matrix of the cornea, and activation of
cornea-degrading enzymes from inflammatory cells (2).
Herpes simplex keratitis is a common cause of corneal
ulceration and blindness worldwide. When antiviral agents
become ineffective, corneal perforation frequently results
in destructive complications. Additionally, in these cases,
if the patients undergo corneal transplantation, there is
an increasing incidence of immune rejection due to the
presence of ongoing active inflammation (3,4).
Bacterial keratitis is also a serious ocular condition and
requires treatment with intensive topical broad-spectrum
antibiotics that are potentially toxic to the corneal
epithelium (5).
* Correspondence: altayye@yahoo.com

The main therapeutic goals for infectious keratitis are to
eliminate the pathogens and to prevent irreversible corneal
structural damage (6). Various adjunctive modalities have
been used in addition to antibiotic/antiviral therapy,
which include steroids, nonsteroidal antiinflammatory
drugs, ascorbic acid, doxycycline, hyperbaric oxygen, and
amniotic membrane transplantation (AMT) (6–9).
In 1997, Lee and Tseng first used human amniotic
membrane (AM) for epithelial defects (10). The AM does
not express the antigens HLA-A, -B, or -DR and therefore
poses no problem of immunological rejection (11). AM
has been used in vivo as a substrate for epithelial growth, in
the management of persistent epithelial defects following
infection, in neurotrophic corneas, in chemical injuries, and
for recurrent erosion syndrome and persistent epithelial
defects associated with cicatricial conditions (9,12). Other
indications include pterygium surgery and pain relief in
bullous keratopathy (13). The AM, consisting of a thick
basement membrane and avascular stromal matrix, is able
to express multiple antiinflammatory, antimicrobial, and
antiangiogenic factors and protease inhibitors (13,14).
AMT is effective in promoting epithelial healing and in
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reducing inflammation, scarring, and angiogenesis (15).
We report a series of patients with herpetic and
bacterial ulcers who were treated with AMT combined
with antimicrobial and corticosteroid therapy.
2. Materials and methods
Chart review of 84 patients with bacterial and herpetic
stromal keratitis who underwent AMT between 2010
and 2013 was performed retrospectively. The study was
approved by the Institutional Review Board and was
in accordance with the principles of the Declaration
of Helsinki. All patients gave informed consent before
treatment.
Patients were divided into 2 groups according to
etiology of ulcerative corneal keratitis: group 1 due to
herpetic stromal keratitis (42 patients), and group 2 due
to bacterial keratitis (42 patients). Clinical data including
patients’ demographic features, etiology, ulcer localization,
dimension and depth, surgical procedure, epithelialization
time after AMT, uncorrected visual acuity (UCVA), and
follow-up period were retrieved retrospectively. Surgical
success was defined as complete epithelialization of ocular
surface, cessation of stromal inflammation, and formation
of a visible stromal thickness.
Briefly, patients with ulcerative keratitis demonstrate
an ulcer with a dense, whitish inflammatory infiltration
with stromal edema. Additionally, in herpetic keratitis,
keratic endothelial precipitates confined to the area of
corneal involvement are commonly present. Diagnostic
criteria were based on ocular examination, previous
reports, and smears and cultures of corneal tissue. The
majority of patients with herpetic keratitis had a history of
recurrent episodes of corneal disease.
Eyes with perforated corneal ulcers, children under 12
years old, cases of concomitant stem-cell deficiency, and
patients undergoing immunosuppressive treatment were
excluded from the study.
Photographs of the eyes were taken at the initial
presentation and follow-up visits. The size of the corneal
ulcer was measured at its greatest diameter. Depth of the
ulcer was also noted (as deep as or less than one-half of
corneal thickness). Smears and cultures were obtained for
microbiological studies at the first visit. In the herpetic
keratitis group, systemic acyclovir at 5 × 400 mg daily
was administered for 1 month, and then 2 × 400 mg daily
for 11 months. In the bacterial keratitis group, frequent
topical antibiotic treatment was continued according to
clinical response. In culture-positive patients, antibiotic
treatment was modified according to culture results. After
2 to 5 days of initial treatment, AMT was performed in all
eyes. Antiviral and antibiotic medications were continued;
topical 0.1% prednisolone acetate 3 × 1 and intensive
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lubrication with artificial tear drops were administered
after surgery.
Amniotic membrane transplantations were performed
using subtenon or general anesthesia. The entire cornea
and limbus were covered by a single or double layer of
cryopreserved AM, which was sutured epithelial side
up at 2 mm posterior to the limbus on the episclera by a
continuous 10–0 nylon suture (overlay technique). The
amniotic basement membrane affords a more suitable
substratum for corneal or conjunctival epithelial cells to
grow on compared to amniotic stroma. The wider spaced
collagen of the stroma retards epithelial spread. Because
of this, AM is placed onto the ocular surface with the
basement membrane (epithelial) side up (13). If the ulcer
depth was more than half the corneal thickness, doublelayer AMT was performed, and each layer of AM was
sutured to the episclera separately.
Human AM was obtained under sterile conditions
from planned cesarean sections after screening the donor
for HIV, hepatitis B and C, and syphilis. The placenta
was cleaned of blood clots with a sterile phosphatebuffered saline solution containing penicillin, 50 µg/mL;
streptomycin, 50 µg/mL; tobramycin, 100 µg/mL; and
amphotericin B, 2.5 µg/mL. The amnion was separated
from the chorion by blunt dissection and flattened onto
nitrocellulose paper with the epithelium side up. The
paper with adherent AM was cut into sheets of 3 × 3 cm
and stored before transplantation at –80 °C in a sterile
vial containing Dulbecco’s modified Eagle medium and
glycerol at a ratio of 1/1. The membrane was thawed for 15
min before use.
All patients were examined on postoperative day 1,
then weekly until complete epithelialization occurred,
then monthly for 3 months, and every 3 months thereafter.
While the AM was in place, epithelialization could not
be easily assessed. After the membrane was largely dissolved
(mean: 10 days), the nylon suture was removed and the
corneal surface was assessed for fluorescein staining. If
epithelialization was not complete and unsatisfactory, a
second AMT procedure was performed.
Statistical analyses were performed by using SPSS 15.
The variables were investigated using visual (histograms)
and analytical (Kolmogorov–Smirnov test) methods to
determine whether or not they were normally distributed.
Descriptive analyses were presented using means and
standard deviations for normally distributed variables.
Comparison of normally distributed variables according
to the type of keratitis were made using Student’s t-test.
Abnormally distributed or ordinal variables were
compared by using a chi-square test. A 5% type-I error
level was used to infer statistical significance.
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3. Results
Eighty-four patients (51 male, 33 female) were enrolled
in this retrospective study. The average age of our patients
was 55.85 ± 19.07 years (range: 17–93), and the average
duration of follow-up was 14.70 ± 11.75 months (range:
3–52). Patients were sorted into 2 groups according to
ulcer etiology. Group 1 (42 eyes) included herpetic ulcers
and group 2 (42 eyes) included bacterial ulcers.
There were no statistically significant differences
between the 2 groups in age, initial UCVA, or size and
depth of corneal ulcer at initial presentation (P = 0.33,
P = 0.23, P = 0.22, P = 0.49, respectively). Although
herpetic ulcers were localized more centrally, there was
no significant difference between groups (P = 0.19). In
the herpetic group, 24 patients had corneal scars from
previous herpetic attacks at initial presentation. In the
bacterial group, all patients were primary cases. In this
group, 15 patients had a history of foreign bodies, and 9
patients were chronic contact lens users.
There were only 24 cases with positive culture
results, which might be due to antibiotic treatment that
was started previously. Culture results were as follows:
methicillin-resistant Staphylococcus epidermidis (8 cases),
Streptococcus pneumoniae (6 cases), Staphylococcus aureus
(6 cases), and Pseudomonas aeruginosa (4 cases).
The time of epithelialization was 19.23 ± 7.32 days
(range: 10–36) in the herpetic group compared with 19.31
± 6.30 days (range: 10–35) in the bacterial group. The
difference between groups was not significant (P = 0.95).
Table 1 shows distribution of age, lesion diameter,
lesion depth, and localization between groups with
herpetic ulcers and bacterial ulcers before AMT.
Because of incomplete epithelialization or relapsing
ulcers, 13 eyes (31%) in the herpetic group and 10 eyes

(23.8%) in the bacterial group required a repeat AMT
procedure (Table 2). After mean follow-up of 17.17 ± 13.84
months (range: 5–52), we observed 6 (14.28%) recurrences
in the herpetic ulcer group. No recurrences were observed
in the bacterial ulcer group.
No perforations occurred in eyes of patients in either
group. Only 2 patients in the herpetic group developed
significant corneal thinning and descemetocele;
penetrating keratoplasty was performed for these eyes.
Other patients in both groups completed epithelialization
after 1 or 2 AMT procedures with varying amounts of
corneal scarring (Figures 1 and 2).
Of the herpetic ulcer group, mean initial UCVA less
than 0.1 was 81%, between 0.2 and 0.4 was 11.9%, and
more than 0.5 was 7.1%. Final visual acuity in this group
was 81%, 9.5%, and 9.5%, respectively. There was no
difference between initial and final visual acuity for the
herpetic ulcer group.
In the bacterial ulcer group, initial UCVA less than 0.1
was 90.5%, between 0.2 and 0.4 was 2.4%, and more than 0.5
was 7.1%. Final UCVA in this group was 52.4%, 21.4%, and
26.2%, respectively. There was a significant improvement in
UCVA for the bacterial ulcer group (P = 0.02).
4. Discussion
We have presented the results of AMT in the treatment of
herpetic and bacterial corneal ulcers with a combination
of antimicrobial and topical steroid therapy.
The presence of antiangiogenic and antiinflammatory
factors in the AM helps decrease inflammation and
neovascularization, and it functions as a biological barrier
(14,16). The AM serves as a bandage contact lens before
epithelial healing. This mechanical or physical bandage
effect may decrease pain after AMT surgery (17). Although

Table 1. Distribution of age, lesion diameter, lesion depth, and localization between herpetic and bacterial keratitis groups.
Groups
Variables

Herpetic keratitis
N = 42

Bacterial keratitis
N = 42

P

Age (years)

53.83 ± 17.42

57.88 ± 20.60

0.331

Lesion diameter (mm)

2.85 ± 1.07

3.19 ± 1.41

0.221

Central

20 (47.6)

12 (28.6)

Paracentral

19 (45.2)

26 (61.9)

Peripheral

3 (7.1)

4 (9.5)

<½ of corneal thickness

18 (42.9)

22 (52.4)

≥½ of corneal thickness

24 (57.1)

20 (47.6)

Localization
N (%)
Lesion depth
N (%)

0.192

0.382

Student’s t-test.
Chi-square test.

1
2

459

ALTAY et al. / Turk J Med Sci
Table 2. Comparison of keratitis groups in relation to amnion layers, number of amnion applications, preoperative and postoperative
visions, duration of follow-up, and time for epithelialization.
Groups
Variables

Layers of transplanted amnion
Number of amnion applications

Preoperative vision

Postoperative vision

Herpetic keratitis N = 42

Bacterial keratitis N = 42

Number

Percentage

Number

Percentage

Single

18

42.9

22

52.4

Double

24

57.1

20

47.6

Once

29

69.0

32

76.2

Twice

13

31.0

10

23.8

≤0.1

34

81.0

38

90.5

0.2–0.4

5

11.9

1

2.4

≥0.5

3

7.1

3

7.1

≤0.1

34

81.0

22

52.4

0.2–0.4

4

9.5

9

21.4

≥0.5

4

9.5

11

26.2

P
0.381
0.751
0.231

0.021*

Time for
epithelialization (days)

19.23 ± 7.32
(10–36 days)

19.31 ± 6.30
(10–35 days)

0.952

Duration of
follow-up (months)

17.17 ± 13.84
(5–52 months)

12.29 ± 8.70
(3–38 months)

0.062

Chi-square test.
Student’s t-test.
*Statistically significant difference, chi-square.
1

2

a

b

Figure 1. Picture of a case with bacterial keratitis: a) before amniotic membrane transplantation; b) 5 months after AMT.

pain was not scored in our patients, they did not require
analgesics postoperatively.
The epithelial healing time observed in our series was
similar in each group (mean: 19.27 ± 6.77 days). The AM
acts as a substrate for epithelial growth. It facilitates the
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migration of epithelial cells, strengthens the adhesion of
basal epithelial cells, promotes epithelial differentiation,
and prevents apoptosis (18). In addition, the AM contains
growth factors such as nerve growth factor that may
promote the epithelialization process (19).
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a

b

Figure 2. Picture of a case with herpetic stromal keratitis: a) before amniotic membrane transplantation; b) 15 months after AMT.

The antiinflammatory effect of the AM may be explained
by the fact that the stroma of the AM stimulates apoptosis
of inflammatory cells, suppresses cytokines, and contains
proteinase inhibitors (14). It may also act as a barrier
against the infiltration of polymorphonuclear leucocytes
from tear film. The AM contains tissue inhibitors of matrix
metalloproteinase MMP-1 and MMP-2, and thus inhibits
the destruction of collagen and prevents stromal melting
(20).
When a topical steroid can be initiated is the
critical question, knowing that topical steroid
application potentially prevents host immunity against
microorganisms. An AM can form a useful barrier
by overlying the surface of a corneal ulcer, and it can
prevent ulcer aggravation with topical steroid use. AMT
might counterbalance the potentially damaging effects of
topical steroids while maximizing their antiinflammatory
potential. Shi et al. studied 15 patients with herpetic
necrotizing stromal keratitis; they used AMT combined
with antiviral and steroid therapy, and they did not
observe the steroid compromising wound healing (3).
Gicquel et al. reported early AMT combined with topical
corticosteroids in severe bacterial keratitis without any
corneal perforation (6).
Similarly, neither corneal perforation nor stromal
infiltrate size extension was observed in our series. Only
2 cases in the herpetic group progressed to descemetocele
with repeat herpetic keratitis attacks. When the ulcer depth
was deeper than half the corneal thickness, we used doublelayer AMT (24 eyes in the herpetic group, 20 eyes in the
bacterial group). Along with reepithelialization, multilayer
AMT achieves a stable stromal thickness by filling the
stromal defect with amniotic membrane. RodriquezAres et al. reported a success rate of 73% in a case series
of 15 patients with corneal perforations. They concluded
that multilayer AMT was effective in perforations with
diameters of less than 1.5 mm, and steroids did not delay

deep ulcer healing even in a case with descemetocele (21).
After a mean follow-up of 17.17 ± 13.84 months
(range: 5–52), we observed 6 (14.28%) recurrences in
the herpetic keratitis group. These recurrences may have
been due to diminution of the antiinflammatory effects
of AMT following dissolution. Therefore, antiviral and
antiinflammatory drugs are indispensable in the treatment
of these patients.
Besides its antiinflammatory effect, AM has
antibacterial and antiviral effects on microbial keratitis.
Antimicrobial properties of amnion and chorion have
been reported against a variety of microorganisms
including hemolytic Streptococcus A, S. aureus, E. coli,
and P. aeruginosa (22). Paradowska et al. reported that
AM contained tumor necrosis factors and interferons for
antiviral activity (23).
AM may also act as a long-term drug delivery system
(24). After the addition of ophthalmic solutions, AM
becomes soaked with antibiotics and steroids and it
functions as a depot for drug delivery. In the treatment
of microbial ulcers, AM has antimicrobial properties, it
facilitates epithelialization, it inhibits inflammation and
angiogenesis, it relieves pain, and it functions as a drug
reservoir.
Although final visual acuity in our herpetic ulcer group
was not increased, perforation of the globe was avoided
and inflammation and vascularization were limited by
AMT. All of these functions of the AM are advantages
that will decrease the risk of rejection for future corneal
transplantation.
In conclusion, AMT is a convenient approach for
the treatment of corneal ulcers resistant to conventional
treatment, and it allows the use of early topical steroid
application in microbial ulcers. It can also be used
temporarily in cases requiring keratoplasty at a later time.
The eye will be less inflamed and the cornea surface will
already be reepithelialized by that time.

461

ALTAY et al. / Turk J Med Sci
References
1.

Edelstein SL, Wichiensin P, Huang AJW. Bacterial keratitis.
In: Krachmer JH, Mannis M, Holland EJ, editors. Cornea
Fundamentals, Diagnosis and Management. Volume 1-A. 3rd
ed. Beijing, China: Mosby Elsevier; 2010. pp. 919–944.

2.

Kreger AS. Pathogenesis of Pseudomonas aeruginosa ocular
diseases. Rev Infect Dis 1983; 5: S931–S935.

3.

Shi W, Chen M, Xie L. Amniotic membrane transplantation
combined with antiviral and steroid therapy for herpes
necrotizing stromal keratitis. Ophthalmol 2007; 114: 1476–
1481.

4.

Knickelbein JE, Hendricks RL, Charukamnoetkanok P.
Management of herpes simplex virus stromal keratitis: an
evidence based review. Surv Ophthalmol 2009; 54: 226–234.

5.

Gangopadhyay N, Daniell M, Weih L, Taylor HR.
Fluoroquinolone and fortified antibiotics for treating bacterial
and corneal ulcers. Br J Ophthalmol 2000; 84: 378–384.

6.

Gicquel JJ, Bejjani RA, Ellies P, Mercie M, Dighiero P. Amniotic
membrane transplantation in severe bacterial keratitis. Cornea
2007; 26: 27–33.

7.

8.

Kheirkhah A, Tabatabaei A, Zavareh MK, Khodabandeh A.
A controlled study of amniotic membrane transplantation for
acute Pseudomonas keratitis. Can J Ophthalmol 2012; 47: 305–
311.
Heiligenhaus A, Li H, Hernandez Galindo EE, Koch JM, Steuhl
KP, Meller D. Management of acute ulcerative and necrotising
herpes simplex and zoster keratitis with amniotic membrane
transplantation. Br J Ophthalmol 2003; 87: 1215–1219.

9.

Brijacak N, Dekaris I, Gagro A, Gabric N. Therapeutic effect of
amniotic membrane in persistent epithelial defects and corneal
ulcers in herpetic keratitis. Coll Antropol 2008; 32: 21–25.

10.

Lee S, Tseng SCG. Amniotic membrane transplantation for
persistent epithelial defects with ulceration. Am J Ophthalmol
1997; 123: 303–312.

11.

Dua HS, Azuara-Blanco A. Amniotic membrane
transplantation. Br J Ophthalmol 1999; 83: 748–752.

12.

Khokhar S, Natung T, Sony P, Sharma N, Agarwal N, Vajpayee
R. Amniotic membrane transplantation in refractory
neurotrophic corneal ulcers: a randomized controlled trial.
Cornea 2005; 24: 654–660.

13.

Dua HS, Gomes JAP, King AJ, Maharajan SV. The amniotic
membrane in ophthalmology. Surv Ophthalmol 2004; 49: 51–
77.

462

14.

Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification
of antiangiogenic and antiinflammatory proteins in human
amniotic membrane. Cornea 2000; 19: 348–352.

15.

Bouchard CS, John T. Amniotic membrane transplantation in
the management of severe ocular surface disease: indications
and outcomes. Ocul Surf 2004; 2: 201–211.

16.

Yildiz EH, Nurozler AB, Aksoy NO, Altiparmak UE, Onat M,
Karaguzel H, Duman S. Amniotic membrane transplantation:
Indications and results. Eur J Ophthalmol 2008; 18: 685–690.

17.

Espana EM, Grueterich M, Sandoval H, Solomon A, Alfonso
E, Carp CL, Fantes F, Tseng SC. Amniotic membrane
transplantation for bullous keratopathy in eyes with poor
visual potential. J Cataract Refract Surg 2003; 29: 279–284.

18.

Wang MX, Gray TB, Park WC, Prabhasawat P, Culbertson W,
Forster R, Hanna K, Tseng SCG. Reduction in corneal haze
and apoptosis by amniotic membrane matrix in excimer laser
photoablation in rabbits. J Cataract Refract Surg 2001; 27: 310–
319.

19.

Touhami A, Grueterich M, Tseng SC. The role of NGF signaling
in human limbal epithelium expanded by amniotic membrane
culture. Invest Ophthalmol Vis Sci 2002; 43: 987–994.

20.

Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic
membrane patching promotes healing and inhibits protease
activity on wound healing following acute corneal alkali burn.
Exp Eye Res 2000; 70: 329–337.

21.

Rodriquez-Ares MT, Tourino R, Lopez-Valladares MJ, Gude
F. Multilayer amniotic membrane transplantation in the
treatment of corneal perforations. Cornea 2004; 23: 577–583.

22.

Kjaaergaard N, Hein M, Hyttel L, Helmig RB, Schonheyder
HC, Uldbjerg N, Madsen H. Antibacterial properties of human
amnion and chorion in vitro. Eur J Obstet Gynecol Reprod Biol
2001; 94: 224–229.

23.

Paradowska E, Blach-Olszewska Z, Sender J, Jaroz W. Antiviral
nonspecific immunity of human placenta at term: possible
role of endogenous tumor necrosis factors and interferons. J
Interferon Cytokine Res 1996; 16: 941–948.

24.

Resch MD, Resch BE, Csizmazia E, Imre L, Nemeth J, SzaboRevesz P, Csanyi E. Drug reservoir function of human amniotic
membrane. J Ocular Pharma Therapeutics 2011; 27: 323–326.

